Cytochrome P450 2C19 Genotyping Assay
The FDA cleared Luminex xTAG CYP2C19 assay, offered by CMCD, is an in vitro diagnostic test used to simultaneously detect and identify a panel of nucleotide variants found within the highly polymorphic CYP450 2C19 gene, located on the chromosome 10q24, from genomic DNA. The xTAG CYP2C19 is a qualitative genotyping assay which can be used as an aid to clinicians in determining therapeutic strategy for therapeutics that are metabolized by the CYP2C19 gene product, specifically *2, *3, and *17
CYP2C19 acts on 5-10% of drugs in current clinical use. About 2-6% of individuals of European origin, and 10-20% of Africans have a slow acting, poor metabolizer form of this enzyme. However there is wide variability among populations. CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including antidepressants, barbiturates, proton pump inhibitors, antimalarial and antitumor drugs.
(For 2D6 and 2C19)
Please call Client Services at (330) 405-2623 to obtain specimen kits.
Type: Buccal Swabs
Turn Around Time: 5 Days from receipt of specimen in laboratory
The effectiveness of Plavix is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.